)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lipum
Lipum (LIPUM) investor relations material
Lipum has been delisted
Lipum Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary27 Nov, 2025
Executive summary
Advanced to phase 2 clinical development for SOL-116 targeting rheumatoid arthritis, following successful phase 1 results and new scientific data supporting BSSL as a biomarker.
Announced a proposed merger with main shareholder Flerie to secure long-term financing and access to broader resources.
89% participation in new employee and board stock option programs; new CFO appointed.
Financial highlights
Operating income for Q3: 457 KSEK (109 KSEK year-over-year), mainly from grants.
Operating loss for Q3: -13,144 KSEK (-1,632 KSEK year-over-year); net loss after financial items: -14,027 KSEK (-1,680 KSEK year-over-year).
Cash and cash equivalents at period end: 5,627 KSEK (12,873 KSEK year-over-year).
Cash flow from operations Q3: -7,730 KSEK (-7,258 KSEK year-over-year); financing inflow of 11,683 KSEK from loans and options.
Outlook and guidance
Additional financing required to initiate phase 2 study in H1 2026; merger with Flerie expected to secure necessary capital.
Ongoing scientific collaborations and clinical progress support continued development of SOL-116.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lipum
- Mitazalimab shows significant survival gains in pancreatic cancer, with phase III trials imminent.LIPUM
Investing in Life Science 2025 - Phase 1 success for SOL-116 enables phase 2 plans, but further funding and risk management are critical.LIPUMQ2 2025
- Phase 1 trial for SOL-116 nearly complete; strong cash position but further funding required.LIPUMQ3 2024
- Phase 1 for SOL-116 nearly complete; strong liquidity and positive interim results support phase 2.LIPUMQ2 2024
- Phase 1 success for SOL-116 sets stage for phase 2, but further funding is required.LIPUMQ1 2025
- Phase 1 success for SOL-116 and new funding set stage for Lipum's phase II ambitions.LIPUMQ4 2024
Lipum
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lipum is a biotechnology company focused on developing novel treatments for chronic inflammatory diseases. Its research targets specific proteins involved in inflammation pathways, with the aim of developing biological drug candidates for autoimmune conditions. The company is headquartered in Umeå, Sweden, and its shares are listed on the Nasdaq First North Growth Market.